Banque Cantonale Vaudoise increases its stake in Illumina, Inc. (NASDAQ:ILMN)

Banque Cantonale Vaudoise grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 182.3% during the second quarter, HoldingsChannel reports. The firm owned 3,698 shares of the life sciences company’s stock after buying an additional 2,388 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Illumina were worth $386,000 at the end of the most recent quarter.

A number of other large investors have recently made changes to their positions in ILMN. Trivant Custom Portfolio Group LLC boosted its stake in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after purchasing an additional 125 shares during the period. Versant Capital Management Inc raised its stake in shares of Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the period. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina in the second quarter valued at $34,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after buying an additional 132 shares during the period. Finally, MeadowBrook Investment Advisors LLC acquired a new position in shares of Illumina in the 4th quarter worth $42,000. Hedge funds and other institutional investors own 89.42% of the company’s shares.

Illumina trading down 1.8%

Shares of ILMN opened at $131.40 on Tuesday. Illumina, Inc. it has a one year low of $89.00 and a one year high of $171.50. The stock has a 50-day moving average price of $119.69 and a 200-day moving average price of $121.46. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86, and a current ratio of 1.11. The company has a market cap of $20.93 billion, a P/E ratio of -16.12 and a beta of 1.15.

Illumina (NASDAQ:ILMN – Get Your Free Report ) last posted its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.12 by $0.24. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company’s revenue fell 5.4% year over year. During the same period in the previous year, the business posted EPS of $0.32. Sell-side analysts estimate that Illumina, Inc. will post 3.89 EPS for the current fiscal year.

Changes in Analyst Ratings

A number of brokerage houses intervened on ILMN. Barclays raised Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 target price on the stock in a research note on Wednesday, August 14th. Piper Sandler dropped their price objective on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Jefferies Financial Group assumed coverage on Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective for the company. StockNews.com assumed coverage on Illumina in a report on Thursday, August 29th. They set a “buy” rating for the company. Finally, Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Illumina currently has a consensus rating of “Moderate Buy” and an average target price of $151.05, based on data from MarketBeat.

Get the latest report on Illumina

About Illumina

(Free report)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom and internationally. It works through Core Illumina and GRAIL segments. The company offers sequencing and array instruments and supplies, which include reagents, flow cells and library preparation; whole genome sequencing kits, which sequence whole genomes of various sizes and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured stories

Want to see what other hedge funds own ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Get news and reviews for Illumina Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Illumina and related companies with MarketBeat.com’s FREE daily email newsletter.